Lysophosphatidic Acid-Activated Calcium Signaling Is Elevated in Red Cells from Sickle Cell Disease Patients

• Main Authors: Jue Wang, Laura Hertz, Sandra Ruppenthal, Wassim El Nemer, Philippe Connes, Jeroen S. Goede, Anna Bogdanova, Lutz Birnbaumer, Lars Kaestner
• Format: Article
• Language: English
• Published: MDPI AG 2021-02-01
• Series: Cells
• Subjects: erythrocytes; sickle cell disease; LPA receptor; G protein signaling; transgenic mice; protein kinase Cα
• Online Access: https://www.mdpi.com/2073-4409/10/2/456
• ISSN: 2073-4409

(1) Background: It is known that sickle cells contain a higher amount of Ca²⁺ compared to healthy red blood cells (RBCs). The increased Ca²⁺ is associated with the most severe symptom of sickle cell disease (SCD), the vaso-occlusive crisis (VOC). The Ca²⁺ entry pathway received the name of P_sickle but its molecular identity remains only partly resolved. We aimed to map the involved Ca²⁺ signaling to provide putative pharmacological targets for treatment. (2) Methods: The main technique applied was Ca²⁺ imaging of RBCs from healthy donors, SCD patients and a number of transgenic mouse models in comparison to wild-type mice. Life-cell Ca²⁺ imaging was applied to monitor responses to pharmacological targeting of the elements of signaling cascades. Infection as a trigger of VOC was imitated by stimulation of RBCs with lysophosphatidic acid (LPA). These measurements were complemented with biochemical assays. (3) Results: Ca²⁺ entry into SCD RBCs in response to LPA stimulation exceeded that of healthy donors. LPA receptor 4 levels were increased in SCD RBCs. Their activation was followed by the activation of G_i protein, which in turn triggered opening of TRPC6 and Ca_V2.1 channels via a protein kinase Cα and a MAP kinase pathway, respectively. (4) Conclusions: We found a new Ca²⁺ signaling cascade that is increased in SCD patients and identified new pharmacological targets that might be promising in addressing the most severe symptom of SCD, the VOC.